Initial Results of Secukinumab Drug Survival in Patients with Psoriasis: A Multicentre Daily Practice Cohort Study

Acta Dermato-Venereologica

Juul M.P.A. van den Reek¹  Wim J.A. de Kort²  Barbara Horvath²  M. David Njoo²  Marjan de Groot²  Martijn B.A. van Doorn²  Marjolein S. De Bruin-Weller²  H. Jorn Bovenschen²  Roland Mommers²  Phyllis I. Spuls²  Elke M.G.J. de Jong²  Ruud L.M.A. Prevoo²  Peter C.M. van de Kerkhof²  Wietske Kievit²  Lieke J. van Vugt²  Paul M. Ossenkoppele²  Georges P.H. Lucker²  Gayle E. van der Kraaij² 

[1] Department of Dermatology, Radboud University Medical Centre, PO Box 9101, NL-6500 HB Nijmegen, The Netherlands. [e-mail]. ;;

关键词: psoriasis;    secukinumab;    biologics;    drugsurvival;    effectiveness.;   

DOI  :  10.2340/00015555-2900

来源: DOAJ

【 摘 要 】

Interleukin 17-antagonist secukinumab demonstrated high efficacy for treatment of psoriasis in randomized controlled trials. However, performance in daily practice may differ from trials. Drug survival is a comprehensive outcome covering effectiveness and safety, suitable for analyses of daily practice. The aim of this study was to evaluate drug survival of secukinumab in a daily practice psoriasis cohort. Data were collected from 13 hospitals. Drug survival was analysed using Kaplan–Meier survival curves, split for reason of discontinuation. In total, 196 patients were included (83% biologic experienced). Overall, 12 and 18 months drug survival of secukinumab was 76% and 67%, respectively, and was mostly determined by ineffectiveness. There was a trend towards shorter drug survival in women and in biologic experienced patients. Thirteen percent of patients experienced at least one episode of fungal infection. This is one of the first studies of drug survival of secukinumab in patients with psoriasis treated in daily practice.

【 授权许可】

Unknown